Idiopathic Pulmonary Fibrosis (IPF)

Features

Hagit Baris-Feldman

Israel Emerges as Global Powerhouse in Rare Disease Research

TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…

Treating IPF Patients in the Age of COVID-19

NEW YORK, New York — Noah Greenspan, DPT, says the pulmonary fibrosis (PF) patients and others who had been coming to his Pulmonary Wellness and Rehabilitation Center until he closed it in March 2020 in the wake of the COVID-19 pandemic were among “the oldest, sickest, most complex patients in the book.”  Since then, the…
NORD t-shirts for sale

NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards

Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…

IPF Clinical Insights

The Impact of the 2018 Diagnostic Guidelines on Clinical Outcomes in IPF

As clinicians, we are keenly aware that guidelines on the diagnosis and treatment of a disease change, as continuous research provides additional clarity and information. In the UK, this is perhaps most poignantly reflected in the British National Formulary, which is essentially a book on the latest British guidelines for drug prescription. The book is…
IPF prognosis

Prognosis in IPF Remains Poor Amid a Lack of Consensus on Treatment Approach

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown origin. Interstitial lung disease in itself is an umbrella term for various diseases that cause inflammation, cellular proliferation, and fibrosis of lung tissue. The fibrosis of the lung replaces healthy tissue with a modified extracellular matrix that deeply damages it.  There is much we…

Rare Care Podcast

Diagnosing and Treating IPF: Insights From Noah Greenspan, DPT, founder of New York City’s Pulmonary Wellness & Rehabilitation Center.


PPF Meeting Coverage